RxDoctor Payments Data

Bracken Lewis, MD

Internal Medicine · Greenville, KYNPI 1851478085

Payments from drug & device makers

$326in general payments, 2019–2025

Across 20 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$122
  • Johnson & Johnson$69
  • Lilly USA, LLC$44
  • Abbott$31
  • Sunovion Pharmaceuticals Inc.$17
  • Astellas Pharma US Inc$15
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$326 in reported general payments places this provider in the 45th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$11,307
Medicare patients
434
Services billed
996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide598$662,051
JardianceEmpagliflozin435$354,579
FarxigaDapagliflozin Propanediol389$296,885
EliquisApixaban288$221,613
JanuviaSitagliptin Phosphate126$95,301
Repatha SureclickEvolocumab149$95,212
MounjaroTirzepatide72$93,055
Trelegy ElliptaFluticasone/Umeclidin/Vilanter124$90,812
Tresiba Flextouch U-200Insulin Degludec73$72,180
TrulicityDulaglutide53$67,933
Tresiba Flextouch U-100Insulin Degludec124$65,286
InvokanaCanagliflozin49$43,780
KerendiaFinerenone60$41,026
XifaxanRifaximin13$36,863
XareltoRivaroxaban47$35,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$122$707,762636 claims
Lilly USA, LLCMounjaro, Trulicity$44$160,987125 claims
Johnson & JohnsonInvokana, Xarelto$69$79,40496 claims
BayerKerendia$13$41,02660 claims
AmgenProlia$15$26,46415 claims
Astellas Pharma US IncMyrbetriq$15$17,68037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Greenville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →